Natco Pharma, a Telangana-based pharmaceutical company, saw its shares plummet to the abyss, losing double digits (over 19 per cent) in the intraday trade on Thursday, February 13.
Natco Pharma Q3
This major development came to pass after the company released its Q3 results.
While the equity markets look to stabilise themselves amid significant volatility, the earnings season is also exhibiting its impact on individual stocks, if not the markets as a whole.
Profits In A Pitfall
This result from Natco however, was overwhelmingly negative. The company recorded a major decline in its overall profit margin.
As per the exchange filing, the company, as per the statement on consolidated results, saw its profits for the third quarter stumble to Rs 132.4 crore.
This is about 80 per cent lower than the total profit attained by the company in quarter right before that, or Q2 of FY25, when the company accrued profits of Rs 676.5 crore.
As per the exchange filing, the company, as per the statement on consolidated results, saw its profits for the third quarter stumble to Rs 132.4 crore.
|
Even when compared to the previous fiscal year, the total profits for the period declined by nearly half. In Q3 of FY24, the company saw profits of Rs 212.7 crore.
The company’s total income also nearly halved compared to Q2. The total income reported in Q3 stands at Rs 651.1 crore.
Meanwhile, in Q2 of FY25 (the quarter that ended in September 2024), the company recorded profits of Rs 1,434.9 crore. In the previous fiscal cycle (Q3 FY24), the company saw a total income of Rs 795.6 crore.
Natco Shares On Thursday
When we take a closer look at the company shares, it has been a cataclysmic day at Dalal Street for the pharma firm. After declining by over a staggering 19 per cent, the progress of the decline subdued a little while continuing to trade with deep cuts.
At the time of writing, the overall decline inflicted in the day stood at 17.95 per cent or Rs 218.75, this took the overall value of the company shares to Rs 1,000.05.
